CO2017005784A2 - Compuestos bicíclicos fusionados para el tratamiento de enfermedades - Google Patents
Compuestos bicíclicos fusionados para el tratamiento de enfermedadesInfo
- Publication number
- CO2017005784A2 CO2017005784A2 CONC2017/0005784A CO2017005784A CO2017005784A2 CO 2017005784 A2 CO2017005784 A2 CO 2017005784A2 CO 2017005784 A CO2017005784 A CO 2017005784A CO 2017005784 A2 CO2017005784 A2 CO 2017005784A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- treatment
- fused bicyclic
- bicyclic compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083031P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/062017 WO2016081918A1 (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017005784A2 true CO2017005784A2 (es) | 2017-10-31 |
Family
ID=56014622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0005784A CO2017005784A2 (es) | 2014-11-21 | 2017-06-12 | Compuestos bicíclicos fusionados para el tratamiento de enfermedades |
Country Status (17)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US10689383B2 (en) | 2014-08-04 | 2020-06-23 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| EP3221321B1 (en) * | 2014-11-21 | 2021-12-15 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| EP3274350A1 (en) * | 2015-03-26 | 2018-01-31 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| CN109843298A (zh) * | 2016-05-25 | 2019-06-04 | 阿卡纳治疗学有限公司 | 利用法尼酯x受体(fxr)调节剂的组合疗法 |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| KR102269305B1 (ko) | 2016-06-13 | 2021-06-25 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| RU2019144064A (ru) * | 2017-06-02 | 2021-07-13 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| CN118388474A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| JP2022541503A (ja) | 2019-07-23 | 2022-09-26 | ノバルティス アーゲー | Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置 |
| WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| CN114630681A (zh) | 2019-09-03 | 2022-06-14 | 诺华股份有限公司 | 包含actrii受体拮抗剂的肝疾病或障碍的治疗 |
| WO2021053618A1 (en) | 2019-09-19 | 2021-03-25 | Novartis Ag | Treatment comprising fxr agonists |
| JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| KR20220119424A (ko) | 2019-12-20 | 2022-08-29 | 노파르티스 아게 | 인테그린 억제제를 사용한 간 질환의 조합 치료 |
| PE20230240A1 (es) | 2019-12-20 | 2023-02-07 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| AR123313A1 (es) * | 2020-08-24 | 2022-11-16 | Adama Makhteshim Ltd | Proceso para la preparación de pirazoles sustituidos |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| JP4679517B2 (ja) * | 2003-07-23 | 2011-04-27 | エグゼリクシス， インコーポレイテッド | 薬剤としてのアゼピン誘導体 |
| EA010905B1 (ru) * | 2003-09-17 | 2008-12-30 | Янссен Фармацевтика Н.В. | Сопряжённые гетероциклические соединения |
| US20090137554A1 (en) * | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| JP2012503654A (ja) * | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | １，２，３，６−テトラヒドロアゼピノ［４，５−ｂ］インドール−５−カルボキシレート核内受容体阻害剤 |
| US8252826B2 (en) * | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| EP3221321B1 (en) * | 2014-11-21 | 2021-12-15 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| KR20190040140A (ko) * | 2016-05-25 | 2019-04-17 | 아카나 테라퓨틱스, 엘티디. | 질환의 치료를 위한 융합된 비시클릭 화합물 |
-
2015
- 2015-11-20 EP EP15861717.5A patent/EP3221321B1/en active Active
- 2015-11-20 CN CN201580073351.8A patent/CN107207513B/zh not_active Expired - Fee Related
- 2015-11-20 KR KR1020177016606A patent/KR20170117020A/ko not_active Ceased
- 2015-11-20 MY MYPI2017701793A patent/MY192927A/en unknown
- 2015-11-20 WO PCT/US2015/062017 patent/WO2016081918A1/en not_active Ceased
- 2015-11-20 MX MX2017006694A patent/MX370480B/es active IP Right Grant
- 2015-11-20 AU AU2015349687A patent/AU2015349687B2/en not_active Ceased
- 2015-11-20 SG SG10202010386PA patent/SG10202010386PA/en unknown
- 2015-11-20 JP JP2017545870A patent/JP7224102B2/ja active Active
- 2015-11-20 CA CA2968434A patent/CA2968434A1/en active Pending
- 2015-11-20 ES ES15861717T patent/ES2911293T3/es active Active
- 2015-11-20 CN CN202010634386.7A patent/CN111662297A/zh active Pending
- 2015-11-20 RU RU2017121588A patent/RU2706007C2/ru active
- 2015-11-20 SG SG11201703953WA patent/SG11201703953WA/en unknown
-
2017
- 2017-05-16 IL IL252309A patent/IL252309B/en active IP Right Grant
- 2017-05-19 US US15/599,647 patent/US10233187B2/en active Active
- 2017-05-19 CL CL2017001289A patent/CL2017001289A1/es unknown
- 2017-05-20 SA SA517381566A patent/SA517381566B1/ar unknown
- 2017-06-12 CO CONC2017/0005784A patent/CO2017005784A2/es unknown
-
2019
- 2019-03-15 US US16/354,879 patent/US20190308977A1/en not_active Abandoned
-
2020
- 2020-07-22 JP JP2020125592A patent/JP2021011482A/ja active Pending
- 2020-09-18 US US17/025,724 patent/US20210147426A1/en not_active Abandoned
- 2020-10-08 AU AU2020250270A patent/AU2020250270B2/en not_active Ceased
-
2022
- 2022-09-16 US US17/932,876 patent/US20230183247A1/en not_active Abandoned
- 2022-10-26 JP JP2022171339A patent/JP2023011731A/ja active Pending
-
2024
- 2024-06-27 US US18/757,057 patent/US20250171446A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CL2017000806A1 (es) | Compuestos anti-tnf | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| HRP20180697T1 (hr) | Spojevi imidazo[4,5-c]kinolin-2-ona i njihova upotreba za liječenje raka | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| HUE051296T2 (hu) | Benzoxazinon-származékok bõrbetegségek kezelésére | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| HRP20180788T1 (hr) | [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti | |
| ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
| DE112015002229A5 (de) | Formulierungen zur Behandlung von Hyperthyreose | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| LT3290436T (lt) | Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui |